<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; non-proprietory</title>
	<atom:link href="http://www.tapanray.in/tag/non-proprietory/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier</title>
		<link>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/#comments</comments>
		<pubDate>Mon, 04 Apr 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[lantus XR]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[non-proprietory]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[pen]]></category>
		<category><![CDATA[pre-filled]]></category>
		<category><![CDATA[prescriber]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toujeo]]></category>
		<category><![CDATA[uncharted]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7578</guid>
		<description><![CDATA[A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
